Abstract
To provide an antibody that specifically binds to an extracellular domain of human LPA1, wherein the antibody does not specifically bind to an extracellular domain of human LPA2 and does not specifically bind to an extracellular domain of human LPA3. Preferably, the antibody includes an activity of blocking an LPA1-dependent cell function. Also, a nucleic acid encoding the antibody, a cell including the nucleic acid, and a medicament including the antibody as an active ingredient are provided.
Full Text
What is claimed is:
To provide an antibody that specifically binds to an extracellular domain of human LPA1, wherein the antibody does not specifically bind to an extracellular domain of human LPA2 and does not specifically bind to an extracellular domain of human LPA3. Preferably, the antibody includes an activity of blocking an LPA1-dependent cell function. Also, a nucleic acid encoding the antibody, a cell including the nucleic acid, and a medicament including the antibody as an active ingredient are provided.
Timeline
Filed
05/01/2026Published
08/20/2026Granted
Not AvailableIPC Codes(2)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 47/68:the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment